This post was originally published on this site Alcon, a Novartis sub-arm specializing in eye care, has announced it received European CE Mark for its AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery. This approval comes right after Alcon’s CE Mark for its trifocal presbyopia-correcting AcrySof IOL, in June 2015. The new…
This post was originally published on this site Sterubin, an active chemical compound extracted from a native California plant, was found to hold neuroprotective and anti-inflammatory potential for Alzheimer’s disease, a study shows. The study, “Old age-associated phenotypic screening for Alzheimer’s disease drug candidates identifies sterubin as a potent neuroprotective compound from Yerba santa,” was…
This post was originally published on this site Children born to obese mothers are known to be at an increased risk of obesity, but researchers do not fully understand why. A recent study by a research team in Brazil has found one possible reason: the umbilical cells of babies born to obese or overweight women have a modified expression…
This post was originally published on this site A Phase 1 clinical trial in healthy volunteers for investigational therapy AZP2006 — an oral medicine that is meant to clear accumulations of toxic proteins in Alzheimer’s disease and progressive supranuclear palsy — has shown positive results, says the therapy’s developer, AlzProtect. Progressive supranuclear palsy (PSP) is a rare, progressive disease…
This post was originally published on this site Obesity is a risk factor for more cancers than previously believed, according to the results of a new evaluation conducted by the IARC Handbooks of Cancer Prevention program under the World Health Organization. The conclusions were based on the results of a systematic review of more than 1,000…
This post was originally published on this site Denali Therapeutics has begun dosing patients in its Phase 1b clinical trial of DNL747 as a treatment for Alzheimer’s disease. “We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS [central nervous system] penetration, and target engagement, at the…
This post was originally published on this site A Phase 2 trial is enrolling patients with moderate Alzheimer’s to test an investigational antibody known as RO7105705 that targets the Tau protein. The Genentech-sponsored multicenter, randomized study (NCT03828747) intends to assess the efficacy, safety, and pharmacological profile of RO7105705. The company plans to recruit 260 patients…
This post was originally published on this site Obesity is a major risk factor for several diseases, including type 2 diabetes and cardiovascular disease, and a vast majority of the patients with type 2 diabetes are overweight or obese. However, according to a recent study, doctors prescribe 15 times more anti-diabetes medications than those for obesity. Currently…
This post was originally published on this site All his life, Greg O’Brien has had a front-row seat for Alzheimer’s disease. Growing up on Cape Cod, Massachusetts, he was the caregiver in a family of 10 children for his mother. His maternal grandfather and paternal uncle had Alzheimer’s, and his father was diagnosed with dementia…
This post was originally published on this site Exercise has repeatedly been shown in studies to benefit people with type 2 diabetes, but by varying degrees. Now, researchers from Massey University’s School of Sport and Exercise have discovered a protein that may help to ease these differences, so that more diabetics gain in the glucose control brought on by…
